Changes in Hong Kong stocks | Jinxin Reproduction (01951) rose more than 11%, and the national maternity allowance policy is expected to be implemented. The company is a leader in the private assisted reproduction industry

Zhitongcaijing · 03/14 02:57

The Zhitong Finance App learned that Jinxin Reproduction (01951) rose by more than 11%. As of press release, it had risen 11.9% to HK$2.82, with a turnover of HK$233 million.

According to the news, on March 13, the Hohhot Municipal Health Commission issued childcare allowance rules, of which the maximum allowance for a single child can reach 100,000 yuan. The CITIC Securities Research Report pointed out that according to the statement made by the director of the National Health and Health Commission during the conference, childcare allowances will be distributed in 2025, and relevant operation plans are being drafted together with relevant departments. The bank believes that childcare allowances are one of the key measures to solve the problem of low fertility and help boost the desire to have children. Previously, some cities had paid childcare allowances, and the results of the recovery in the local fertility rate have already been shown. It is expected that national-level subsidies will expand the scope of benefits. Although the amount of subsidies is not yet clear, the boosting effect is expected to be clear. It is recommended to actively pay attention to relevant sector opportunities benefiting from increased birth rates, including assisted reproduction.

According to reports, Jinxin Fertility is a provider of assisted reproduction and maternal and child medical services. Its medical institutions are distributed in mainland China, Hong Kong, the United States and Southeast Asia. Zhongtai Securities previously stated that considering that the company is a leader in the assisted reproduction industry with leading market share, significant competitive advantage, steady endogenous growth, and strong epitaxial expansion, it is expected to grow into the number one private assisted reproduction brand and maintain a “buy” rating.